Dirk Müller-Wieland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6610252/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Feasibility of Wearable-Based Remote Monitoring in Patients During Intensive Treatment for Aggressive Hematologic Malignancies. JCO Clinical Cancer Informatics, 2022, 6, e2100126.	2.1	3
2	Diabetes Mellitus and the Heart. Experimental and Clinical Endocrinology and Diabetes, 2022, , .	1.2	1
3	Position Paper on Lipid Therapy in Patients with Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2022, , .	1.2	Ο
4	Definition, Classification and Diagnosis of Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S1-S8.	1.2	28
5	Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S80-S112.	1.2	5
6	Early risk markers for severe clinical course and fatal outcome in German patients with COVID-19. PLoS ONE, 2021, 16, e0246182.	2.5	7
7	Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis. Diabetes Therapy, 2021, 12, 1073-1097.	2.5	5
8	Glycaemic Control with Insulin Glargine 300ÂU/mL in Individuals with TypeÂ2 Diabetes and Chronic Kidney Disease: A REALI European Pooled Data Analysis. Diabetes Therapy, 2021, 12, 1159-1174.	2.5	4
9	Six Months Follow-Up of Patients with Invasive Mechanical Ventilation Due to COVID-19 Related ARDS. International Journal of Environmental Research and Public Health, 2021, 18, 5861.	2.6	20
10	Elevated serum SDMA and ADMA at hospital admission predict in-hospital mortality of COVID-19 patients. Scientific Reports, 2021, 11, 9895.	3.3	18
11	Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit. Scientific Reports, 2021, 11, 2256.	3.3	35
12	Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Results from the REALI European Pooled Analysis. Diabetes Therapy, 2021, , .	2.5	3
13	Development of the Metabolic Syndrome: Study Design and Baseline Data of the Lufthansa Prevention Study (LUPS), A Prospective Observational Cohort Survey. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 777-787.	1.2	2
14	Reliable Detection of Atrial Fibrillation with a Medical Wearable during Inpatient Conditions. Sensors, 2020, 20, 5517.	3.8	13
15	Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. Respiratory Medicine, 2020, 174, 106197.	2.9	235
16	Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study. Advances in Therapy, 2020, 37, 3863-3877.	2.9	7
17	Lipodystrophies—Disorders of the Fatty Tissue. International Journal of Molecular Sciences, 2020, 21, 8778.	4.1	18
18	Physiological Disturbance in Fatty Liver Energy Metabolism Converges on IGFBP2 Abundance and Regulation in Mice and Men. International Journal of Molecular Sciences, 2020, 21, 4144.	4.1	22

#	Article	IF	CITATIONS
19	Differential glycaemic control with basal insulin glargine 300 <scp>U/mL</scp> versus degludec 100 <scp>U/mL</scp> according to kidney function in type 2 diabetes: A subanalysis from the <scp>BRIGHT</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1369-1377.	4.4	26
20	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. European Journal of Preventive Cardiology, 2020, 27, 1663-1674.	1.8	9
21	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovascular Diabetology, 2020, 19, 14.	6.8	22
22	The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2671-2684.	3.8	28
23	PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk. Current Atherosclerosis Reports, 2019, 21, 40.	4.8	6
24	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5253-5262.	3.6	4
25	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovascular Diabetology, 2019, 18, 149.	6.8	27
26	Fatty Liver Due to Increased de novo Lipogenesis: Alterations in the Hepatic Peroxisomal Proteome. Frontiers in Cell and Developmental Biology, 2019, 7, 248.	3.7	23
27	Adipokinome Signatures in Obese Mouse Models Reflect Adipose Tissue Health and Are Associated with Serum Lipid Composition. International Journal of Molecular Sciences, 2019, 20, 2559.	4.1	17
28	Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S73-S92.	1.2	38
29	Definition, Classification and Diagnosis of Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S1-S7.	1.2	263
30	Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care. EPMA Journal, 2019, 10, 445-464.	6.1	96
31	Diabetes Mellitus and the Heart. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S102-S104.	1.2	4
32	Position Paper on Lipid Therapy in Patients with Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S97-S101.	1.2	0
33	Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. Diabetes, Obesity and Metabolism, 2018, 20, 1632-1641.	4.4	15
34	Alirocumab vs usual lipidâ€lowering care as addâ€on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DMâ€DYSLIPIDEMIA randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1479-1489.	4.4	76
35	Insulin Resistance and Vulnerability to Cardiac Ischemia. Diabetes, 2018, 67, 2695-2702.	0.6	31
36	Survey to estimate the prevalence of type 2 diabetes mellitus in hospital patients in Germany by systematic HbA1c measurement upon admission. International Journal of Clinical Practice, 2018, 72, e13273.	1.7	11

#	Article	IF	CITATIONS
37	Higher HbA1c Measurement Quality Standards are Needed for Follow-Up and Diagnosis: Experience and Analyses from Germany. Hormone and Metabolic Research, 2018, 50, 728-734.	1.5	14
38	Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as addâ€on to metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 2598-2607.	4.4	48
39	Inactivation of SREBP-1a Phosphorylation Prevents Fatty Liver Disease in Mice: Identification of Related Signaling Pathways by Gene Expression Profiles in Liver and Proteomes of Peroxisomes. International Journal of Molecular Sciences, 2018, 19, 980.	4.1	30
40	Definition, classification and diagnostics of diabetes mellitus. Laboratoriums Medizin, 2018, 42, 73-79.	0.6	4
41	Mechanisms of Insulin Resistance in Primary and Secondary Nonalcoholic Fatty Liver. Diabetes, 2017, 66, 2241-2253.	0.6	124
42	Association between copy-number variation on metabolic phenotypes and HDL-C levels in patients with polycystic ovary syndrome. Molecular Biology Reports, 2017, 44, 51-61.	2.3	3
43	Efficacy and safety of alirocumab in insulinâ€treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DMâ€INSULIN</scp> randomized trial. Diabetes, Obesity and Metabolism, 2017, 19, 1781-1792.	4.4	105
44	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovascular Diabetology, 2017, 16, 70.	6.8	25
45	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. European Heart Journal, 2016, 37, 2981-2989.	2.2	142
46	Untargeted mass spectrometric approach in metabolic healthy offspring of patients with type 2 diabetes reveals medium-chain acylcarnitine as potential biomarker for lipid induced glucose intolerance (LGIT). Archives of Physiology and Biochemistry, 2016, 122, 266-280.	2.1	2
47	Peroxisomes compensate hepatic lipid overflow in mice with fatty liver. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 965-976.	2.4	43
48	So close and yet so far: mitochondria and peroxisomes are one but with specific talents. Archives of Physiology and Biochemistry, 2013, 119, 126-135.	2.1	21
49	Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass. PLoS ONE, 2012, 7, e31812.	2.5	141
50	Preventing Phosphorylation of Sterol Regulatory Element-Binding Protein 1a by MAP-Kinases Protects Mice from Fatty Liver and Visceral Obesity. PLoS ONE, 2012, 7, e32609.	2.5	42
51	Identification of a gene variant in the master regulator of lipid metabolism SREBP-1 in a family with a novel form of severe combined hypolipidemia. Atherosclerosis, 2011, 218, 134-143.	0.8	29
52	Phosphorylation of sterol regulatory element-binding protein (SREBP)-1a links growth hormone action to lipid metabolism in hepatocytes. Atherosclerosis, 2010, 213, 156-165.	0.8	36
53	Insulin-activated Erk-mitogen-activated Protein Kinases Phosphorylate Sterol Regulatory Element-binding Protein-2 at Serine Residues 432 and 455 in Vivo. Journal of Biological Chemistry, 2004, 279, 22404-22411.	3.4	99
54	MAP Kinases Erk1/2 Phosphorylate Sterol Regulatory Element-binding Protein (SREBP)-1a at Serine 117 in Vitro. Journal of Biological Chemistry, 2000, 275, 33302-33307.	3.4	139

0

#	Article	IF	CITATIONS
55	SREBP-1 Mediates Activation of the Low Density Lipoprotein Receptor Promoter by Insulin and Insulin-like Growth Factor-I. Journal of Biological Chemistry, 1996, 271, 7128-7133.	3.4	137

56 Dyslipid \tilde{A} \overline{m} ien: Aktuelles Lipid-Management. , 0, , .

5